Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...
Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering ...
Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...
Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results